Based on these findings, the first unimolecular GIP/GLP1 receptor co-agonist was introduced in 2013.23 This peptide exhibited enhanced antihyperglycemic and insulinotropic efficacy, as well as a weight loss effect.23 Dual GIP/GLP-1 receptor co-agonists have been demonstrated to be safe and efficacious in humans,24 and in 2022, tirzepatide was the first GIP/GLP-1 receptor co-agonist to be approved for the treatment of T2DM
But growth changed things
Published online Jul 19, 2023
The boxed-warning row is important and asymmetric: because tirzepatide is approved, its rodent thyroid C-cell finding is formally carried on the label as a warning, whereas CagriSema simply has no label yet
The dose can be increased in increments over time, as tolerated, aiming for optimal efficacy with minimal adverse effects
Contact us today to schedule a consultation and discover which treatment is best suited for your needs